- Home
- CLRB vs KPRX Comparison
CLRB vs KPRX Comparison
Compare CLRB & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- KPRX
- Stock Information
- Founded
- CLRB 2002
- KPRX 1998
- Country
- CLRB United States
- KPRX United States
- Employees
- CLRB N/A
- KPRX N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CLRB Health Care
- KPRX Health Care
- Exchange
- CLRB Nasdaq
- KPRX Nasdaq
- Market Cap
- CLRB 12.8M
- KPRX 9.8M
- IPO Year
- CLRB N/A
- KPRX N/A
- Fundamental
- Price
- CLRB $0.32
- KPRX $3.24
- Analyst Decision
- CLRB Buy
- KPRX Strong Buy
- Analyst Count
- CLRB 2
- KPRX 1
- Target Price
- CLRB $28.00
- KPRX $10.00
- AVG Volume (30 Days)
- CLRB 1.3M
- KPRX 16.2K
- Earning Date
- CLRB 03-13-2025
- KPRX 05-09-2025
- Dividend Yield
- CLRB N/A
- KPRX N/A
- EPS Growth
- CLRB N/A
- KPRX N/A
- EPS
- CLRB N/A
- KPRX 1.69
- Revenue
- CLRB N/A
- KPRX $16,020,000.00
- Revenue This Year
- CLRB N/A
- KPRX N/A
- Revenue Next Year
- CLRB $208.14
- KPRX N/A
- P/E Ratio
- CLRB N/A
- KPRX $1.92
- Revenue Growth
- CLRB N/A
- KPRX N/A
- 52 Week Low
- CLRB $0.22
- KPRX $2.91
- 52 Week High
- CLRB $4.17
- KPRX $6.48
- Technical
- Relative Strength Index (RSI)
- CLRB 51.53
- KPRX 45.14
- Support Level
- CLRB $0.30
- KPRX $3.07
- Resistance Level
- CLRB $0.34
- KPRX $3.53
- Average True Range (ATR)
- CLRB 0.03
- KPRX 0.16
- MACD
- CLRB 0.01
- KPRX 0.01
- Stochastic Oscillator
- CLRB 65.14
- KPRX 53.30
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.